Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Up 1.2% in April: Crecon
June 9, 2025
- Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
- Meiji, Daito to Launch Talks on New Consortium to Stabilize Generic Supply, Boost Profitability
June 6, 2025
- Keytruda Japan’s Top-Selling Drug for 20th Month Running: Encise
June 6, 2025
- Santen’s Myopia Drug Approved in Europe
June 6, 2025
- Towa/CiRA to Launch PII/III Trial of Bromocriptine for Familial AD
June 5, 2025
- Fuji Keizai Issues 2040 Market Outlook for Dermatology, Collagen Diseases and More
June 5, 2025
- Takeda’s Adcetris Widens Label in Europe
June 5, 2025
- Enhertu Entering New Phase of Growth with Early-Line Breast Cancer Data: CEO
June 4, 2025
- Sawai Cuts FY2024 Results after Remitch Ruling, Net Profit Drops by Half
June 4, 2025
- Dupixent’s COPD Use Expected to Benefit Patients with Allergic Symptoms: Professor
June 3, 2025
- Kaken to Codevelop TWOCELLS’ Cell Therapy in Japan
June 3, 2025
- Taiho Out-Licenses LSD1 Inhibitor to Yokohama Upstart
June 3, 2025
- Nxera-Lilly Collab Hits Key Milestone, Triggers Undisclosed Payment
June 3, 2025
- Enhertu Extends Survival as 2nd-Line Gastric Cancer Therapy
June 3, 2025
- Kura/Kyowa Kirin’s AML Drug Accepted for US FDA Review
June 3, 2025
- Fuso Sets Up 8 Billion Yen Credit Line after Remitch Ruling
June 3, 2025
- Bayer Files Low-Dose MRI Contrast Agent Gadoquatrane in Japan
June 3, 2025
- Servier Launches Tibsovo for IDH1-Mutated AML in Japan
June 3, 2025
- Scemblix’s 1st Line Nod Will Take CML Therapy to New Stage: Professor
June 2, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…